Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

H, Kantarjian; NP, Shah; A, Hochhaus; J, Cortes; S, Shah; M, Ayala; B, Moiraghi; Z, Shen; J, Mayer; R, Pasquini; H, Nakamae; F, Huguet; C, Boqué; C, Chuah; E, Bleickardt; MB, Bradley-Garelik; C, Zhu; T, Szatrowski; D, Shapiro; M, Baccarani

doi:10.1056/nejmoa1002315

Public

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

Shared by NobleBlocks on Jun 5, 2010 • 12:00 AM UTC

Authors:

Kantarjian H

Shah NP

Hochhaus A

Abstract

Background Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and progression-free survival among patients with chronic myeloid leukemia (CML) in the chronic phase, after failure of imatinib treatment. We assessed the effic...

Discussions